Outcomes and Associated Factors after Melphalan 140 Mg/m² Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in Patients over 70 Years of Age
Key Points
Outcomes after treatment reveal significant improvement in quality of life and symptom management.
Analysis shows enhanced survival rates among patients over 70 treated with melphalan.
Assessment using autologous hematopoietic cell transplantation highlights its role in managing multiple myeloma.
Indications support further exploration of treatment strategies for older patients to enhance care.